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consistent with cannabidiol lacking CB1 receptor agonist or antagonist activity in vivo, demonstrate enhancement of the effects of  9 -THC by cannabidiol, albeit at cannabidiol amounts larger than those in Cannabis or cannabidiol-based therapeutics (nabiximols). In addition to
showing that cannabidiol and a 5-HT1A receptor agonist have overlapping behavioral effects, the current results suggest that 5-HT1A agonism enhances the CB1 receptor-mediated effects of  9 -THC.
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INTRODUCTION
Among the numerous phytocannabinoids in Cannabis sativa (Hill et al., 2012) ,  9 -tetrahydrocannabinol ( 9 -THC) has been the most widely studied due to its prominent psychopharmacological effects. There is increasing recognition of the contribution of other phytocannabinoids to the in vivo effects of cannabis, as well as interest in isolating phytocannabinoids for drug-like and potential therapeutic effects. Cannabidiol is the second most prevalent phytocannabinoid in Cannabis after  9 -THC and there is increasing evidence to suggest that cannabidiol has anti-inflammatory, anticonvulsant, antiemetic, and antipsychotic activity (Campos et al., 2012; Leo et al., 2016) . Most recently, cannabidiol was approved in a formulation with 
9
-THC under the generic name nabiximols for the treatment of spasticity and neuropathic pain associated with multiple sclerosis.
-THC is a cannabinoid receptor agonist, whereas the mechanism of action of cannabidiol remains unclear. Cannabidiol lacks significant binding affinity for the prototypical cannabinoid receptors CB1 or CB2 (Mechoulam et al., 2002) . While its mechanism of action remains poorly understood, cannabidiol exhibits a diverse pharmacology that includes activity at serotonin (5-hydroxytryptamine; 5-HT) 5-HT1A receptors, G protein-coupled receptors (GPR) 55, transient as described (Stewart and McMahon, 2010; Hruba et al., 2012) . The experiments reported here were approved by the Institutional Animal Care and Use Committee of The University of Texas
Health Science Center at San Antonio, and were conducted according to the "Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research" (National Research Council, 2011) .
Surgery
A chronic indwelling catheter (heparin coated polyurethane, od = 1.68 mm, id = 1.02 mm, Instech Solomon, Plymouth Meeting, PA) was inserted into a femoral or subclavian vein while monkeys were anesthetized with ketamine (10 mg/kg i.m.) and isoflurane (1.5-3.0% inhaled via facemask). The catheter was secured in the vessel with suture silk (coated vicryl, Ethicon Inc., Somerville, New Jersey), which was also used to ligate the section of the vessel adjacent to the catheter insertion. The end of the catheter distal to the vessel was attached to a vascular access port (Mida-cbas-c50, Instech Solomon) located s.c. in the mid-scapular region of the back.
Apparatus
Monkeys were seated in chairs (Model R001, Primate Products, Miami, FL). Feet were secured in shoes containing brass electrodes to which a brief electric stimulus (3 mA, 250 ms) could be delivered from an a/c generator. Discrimination training and test sessions were performed by placing monkeys in operant conditioning chambers ventilated with blower fans. White noise was present for the duration of experimental sessions. Within the chamber was a stainless steel panel containing a left and right lever and a disc above each lever that could be illuminated red.
Experimental events were controlled and recorded by an interface (MedAssociates, St. Albans, VT), a computer, and Med-PC software (MedAssociates).
Drug discrimination procedures
One group of monkeys discriminated Δ Incorrect responses reset the response requirement on the correct lever. Determination of correct levers varied among monkeys, e.g., the right lever was associated with vehicle and the left lever was associated with the training dose, and remained the same for that monkey for the duration of the study. For studies with 8-OH-DPAT, the timeout at the beginning of each cycle was shortened to 5 min to accommodate the relatively short duration of action of 8-OH-DPAT evidenced in pilot experiments measuring disruption of operant responding; however, all other experimental parameters remained the same.
Training sessions consisted of administration of the training dose of the training drug (Δ 9 -THC or rimonabant) or vehicle at the beginning of a cycle. Administration of the training dose at the beginning of a cycle was followed by 0-2 cycles during which vehicle was administered; however, the drug lever was designated as correct during every cycle following administration of the training dose during training sessions. A cycle in which the training dose was administered was preceded by 0-3 cycles, and for these preceding cycles vehicle was administered and the vehicle lever was designated correct. Training sessions in which only vehicle was administered for each cycle consisted of 3-6 cycles and the vehicle lever was designated correct throughout.
Monkeys had previously satisfied the criteria for testing, defined as at least 80% of the total responses occurring on the correct lever and fewer than 5 responses occurring on the incorrect lever prior to satisfying the first FR of the cycle on the correct lever for all cycles for 5 consecutive or 6 of 7 training sessions. Tests were conducted after performance for consecutive training sessions, including both vehicle and drug training sessions, satisfied the test criteria.
Five consecutive responses on either lever postponed the shock schedule during test sessions. The control dose-response functions for each training drug were determined by administering vehicle in the first cycle followed by cumulative i.v. doses increasing by 0.5 log unit in subsequent cycles; doses larger than the rimonabant training dose were incremented in 0.25 log unit (i.e., 1.78 and 3.2 mg/kg). To examine the effects of cannabidiol and 8-OH-DPAT, a dose was administered at the beginning of the first cycle followed by cumulative doses of the training drug (Δ
9
-THC or rimonabant) in subsequent cycles. Cannabidiol was studied from 0.1 mg/kg up to 17.8 mg/kg because 32 mg/kg of cannabidiol produced a convulsion. 8-OH-DPAT was studied at 0.0178, 0.056, and 0.178 mg/kg. The effects of each test drug in combination with a training drug were examined using a within-subjects design (e.g., each monkey served as its own control) in four monkeys, except for cannabidiol tests in the Δ 9 -THC discrimination assay which included six monkeys. Two monkeys discriminating rimonabant contributed to tests with both cannabidiol and 8-OH-DPAT; of the four remaining monkeys in the rimonabant discrimination assay, two were used for tests with cannabidiol and the other two were included in the tests with 8-OH-DPAT.
Control dose-response data for each training drug were calculated separately for the cycle durations of 20 min (cannabidiol) and 10 min (8-OH-DPAT). The control dose-response tests were conducted non-systematically in close temporal proximity to the tests with the various doses of cannabidiol and 8-OH-DPAT.
Drugs
Rimonabant, cannabidiol, and Δ GraphPad Prism version 6.00 (GraphPad Software, La Jolla, CA) using non-linear regression and the following equation Y=100/(1+10^((LogED-X)*slope)) with LogED calculated as LogED50Control + log(ED50Ratio). The analysis included the common slope shared by the doseresponse function of the training drug alone and in combination with the various doses of test drug.
Data analyses
ED50Control is the dose of training drug estimated to produce 50% drug-appropriate responding in the absence of test drug and ED50Ratio is the ratio of the ED50 value of the training drug calculated in the presence of a dose of test drug divided by the ED50 value of the training drug alone. A significant shift in the training drug dose-response function is evidenced by a ratio value with 95% confidence limits that do not include 1.
RESULTS

The effects of Δ 9 -THC alone and in combination with cannabidiol or 8-OH-DPAT
The absolute rate of responding averaged over 5 vehicle training sessions for each respective monkey discriminating Δ -THC lever and this occurred at 17.8 mg/kg ( Fig. 1 top left , triangle over VEH). Cannabidiol doses ranging from 0.1 to 3.2 mg/kg did not significantly modify the discriminative stimulus effects of Δ 9 -THC (see Fig. 1 , diamonds for 3.2 mg/kg of cannabidiol; ineffective doses less than 3.2 mg/kg not shown).
In contrast, 10 and 17.8 mg/kg of cannabidiol significantly increased the potency of Δ 9 -THC to produce discriminative stimulus effects ( Fig. 1 -THC and cannabidiol, alone or in combination ( Fig. 1 bottom left) .
The Δ
9
-THC control dose-response function determined in conjunction with the 8-OH-DPAT tests was strikingly similar to that determined for cannabidiol tests, with vehicle producing 0% drug-lever responding and the training dose (0.1 mg/kg) producing 99% drug-lever responding ( Fig. 1 top right, circles) . 8-OH-DPAT produced a maximum of 3% responding on the Δ (Table 1 right column). These represent 1.7-and 13-fold leftward shifts of the Δ 9 -THC dose-response function.
The largest dose of 8-OH-DPAT (0.178 mg/kg), when tested alone and in combination with Δ 9 -THC, markedly decreased response rate with two of four monkeys responding less than 20% of their individual control response rate ( Fig. 1 bottom right, triangles) .
The effects of rimonabant alone and in combination with cannabidiol or 8-OH-DPAT in monkeys receiving Δ
-THC (1 mg/kg/12 h).
The absolute rate of responding averaged over 5 vehicle training sessions for each respective Δ (Fig. 2 bottom left) .
Determination of the control rimonabant dose-response function during shortened cycles (i.e., from 20 min for tests with cannabidiol to 10 min for tests with 8-OH-DPAT) resulted in increased potency. The ED50 value (95% confidence limits) of rimonabant to produce discriminative stimulus effects in these tests was 0.16 (0.12-0.25) mg/kg (Table 1) . 8-OH-DPAT at a dose of 0.056 mg/kg produced 4% of responses on the rimonabant lever ( Fig. 2 top right, square above VEH). This dose of 8-OH-DPAT significantly attenuated the discriminative stimulus effects of rimonabant in Δ
9
-THC treated monkeys, as evidenced by a dose ratio (95% confidence limits) of 2.1 (1.1-3.1). A larger dose of 8-OH-DPAT (0.178 mg/kg) decreased responding to less than 20% of the control response rate in 3 out of 4 monkeys tested ( Fig. 2 bottom right) .
DISCUSSION
Cannabidiol did not substitute for a 
9
-THC discriminative stimulus and did not substitute for a rimonabant discriminative stimulus in  -THC to produce discriminative stimulus effects. Collectively, the current results suggest that cannabidiol carries negligible risk of increasing the subjective effects of 
-THC, and further suggest that cannabidiol is unlikely to attenuate the subjective effects of  9 -THC. To the extent that subjective effects predict abuse liability, these results suggest that cannabidiol has minimal impact on the abuse liability of  9 -THC. Because  9 -THC is not unanimously selfadministered in non-humans among published studies (Tanda, 2016) , drug discrimination will continue to provide critical insight into mechanisms underlying the abuse-related effects of cannabinoids.
The presence and nature of the interaction between cannabidiol and  9 -THC appears to vary for different effects because previous studies have reported antagonism of some of the effects of 
-THC by cannabidiol in rhesus monkeys. Cannabidiol administered in equal amounts with
-THC attenuated some of the disruptive effects of 
-THC on some types of learning and motor behavior, but did not alter all of the effects of  9 -THC (Wright et al., 2013) . In another study cannabidiol also attenuated the effects of  9 -THC on responding under a fixed interval schedule in rhesus monkeys (Brady and Balster, 1980) , and in that study antagonism was obtained at a dose of cannabidiol 100 times larger than  9 -THC (30 and 0.3 mg/kg, respectively). The interaction in the current study was also obtained at a dose of cannabidiol 100 times greater than the  9 -THC dose, but the direction of the interaction was opposite to that reported previously for ratedecreasing effects. That cannabidiol enhanced the discriminative stimulus effects of 
-THC in the current study and attenuated the rate-decreasing effects of  9 -THC in the previous study at comparable doses in the same species suggests that altered pharmacokinetics cannot explain every type of interaction. Instead, the type of interaction that occurs between cannabidiol and 
-THC appears to vary for different behavioral effects, which could reflect differences in the pharmacological mechanisms that mediate the discriminative stimulus effects of 
-THC versus its rate-decreasing effects, as demonstrated previously for cannabinoids under experimental conditions similar to those of the current study (Rodriguez and McMahon, 2014) . (Russo et al., 2005) . In pre-clinical studies, serotonin 5-HT1A receptors appear to mediate many of the in vivo effects of cannabidiol including anti-anxiety effects (Campos and Guimarães, 2008) , anti-emetic effects (Rock et al., 2012) , and antinociceptive effects (Ward et al., 2014) . -THC alone. Mean data for cannabidiol are n=6, except for discrimination data at 10 and 17.8 mg/kg cannabidiol, which are 5 out of the 6 monkeys tested.
Mean data for 8-OH-DPAT are n=4, except for discrimination data at 0.178 mg/kg 8-OH-DPAT, which are 2 out of the 4 monkeys tested. Mean data for cannabidiol are n=4, except for data at 17.8 mg/kg cannabidiol in combination with 3.2 mg/kg rimonabant, which is one monkey. Mean data for 8-OH-DPAT are n=4, except for discrimination data at 0.178 mg/kg 8-OH-DPAT, which is 1 out of the 4 monkeys tested. 
